Gillis Steven's Form 4 filing
VBI Vaccines Inc/BC (VBIV) · filed Jul 18, 2023
- Accession no.
- 0001493152-23-024786
- Filed
- Jul 18, 2023
- Trade date
- Jul 10, 2023
- Filing delay
- 8 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $1.00M. It was filed 8 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gillis StevenCIK 0001229592 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2023 | Common Shares, no par value per share | PPurchaseAcquired | +609,090 | $1.65F4 | +$1,004,998.5 | 1,043,292 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 10, 2023 | Common Shares | PPurchaseDisposed | −609,090 | –F4 | – | 609,090 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
The 609,090 common shares reported in Table I and accompanying warrants to purchase up to 609,090 common shares reported in Table II of this Form 4 were purchased together at a combined public offering price of $1.65 per share and accompanying warrant, which such combined public offering price included $0.01 per accompanying warrant.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.